BSE Live
Mar 18, 16:01Prev. Close
11.62
Open Price
11.84
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 18, 15:54Prev. Close
11.56
Open Price
11.72
Bid Price (Qty.)
11.97 (364)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Syncom Formulations (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.17 | 0.14 | 0.12 | 0.13 | 0.13 | |
| Diluted EPS (Rs.) | 0.17 | 0.14 | 0.12 | 0.13 | 0.13 | |
| Cash EPS (Rs.) | 0.23 | 0.19 | 0.16 | 0.18 | 0.17 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 1.87 | 1.70 | 1.56 | 1.46 | 1.39 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 1.87 | 1.70 | 1.56 | 1.46 | 1.39 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | |
| Revenue from Operations/Share (Rs.) | 2.63 | 2.39 | 2.03 | 2.37 | 2.36 | |
| PBDIT/Share (Rs.) | 0.28 | 0.22 | 0.21 | 0.25 | 0.25 | |
| PBIT/Share (Rs.) | 0.23 | 0.17 | 0.16 | 0.21 | 0.21 | |
| PBT/Share (Rs.) | 0.22 | 0.16 | 0.15 | 0.20 | 0.21 | |
| Net Profit/Share (Rs.) | 0.18 | 0.14 | 0.11 | 0.14 | 0.13 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 10.63 | 9.04 | 10.15 | 10.51 | 10.47 | |
| PBIT Margin (%) | 8.66 | 6.90 | 7.80 | 8.82 | 8.84 | |
| PBT Margin (%) | 8.41 | 6.78 | 7.57 | 8.65 | 8.81 | |
| Net Profit Margin (%) | 6.93 | 5.93 | 5.45 | 5.76 | 5.63 | |
| Return on Networth / Equity (%) | 9.78 | 8.36 | 7.09 | 9.33 | 9.52 | |
| Return on Capital Employed (%) | 11.65 | 9.19 | 9.42 | 13.31 | 9.00 | |
| Return on Assets (%) | 7.89 | 6.41 | 5.05 | 6.08 | 5.90 | |
| Total Debt/Equity (X) | 0.01 | 0.07 | 0.10 | 0.11 | 0.05 | |
| Asset Turnover Ratio (%) | 113.84 | 107.97 | 92.78 | 105.55 | 104.84 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.12 | 2.39 | 1.98 | 1.57 | 1.43 | |
| Quick Ratio (X) | 2.54 | 1.97 | 1.70 | 1.38 | 1.17 | |
| Inventory Turnover Ratio (X) | 12.79 | 13.61 | 14.37 | 18.47 | 11.89 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 21.15 | 14.65 | 15.07 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 14.77 | 11.33 | 11.69 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 78.85 | 85.35 | 84.93 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 85.23 | 88.67 | 88.31 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 49.78 | 85.11 | 81.90 | 158.97 | 174.01 | |
| EV/Net Operating Revenue (X) | 0.24 | 0.46 | 0.52 | 0.86 | 0.95 | |
| EV/EBITDA (X) | 2.28 | 5.04 | 5.08 | 8.18 | 9.03 | |
| MarketCap/Net Operating Revenue (X) | 0.27 | 0.45 | 0.48 | 0.83 | 0.95 | |
| Retention Ratios (%) | 0.00 | 0.00 | 78.84 | 85.34 | 84.92 | |
| Price/BV (X) | 0.39 | 0.64 | 0.62 | 1.35 | 1.60 | |
| Price/Net Operating Revenue | 0.27 | 0.45 | 0.48 | 0.83 | 0.95 | |
| Earnings Yield | 0.25 | 0.13 | 0.11 | 0.07 | 0.06 |
26.11.2025
Syncom Formula Consolidated September 2025 Net Sales at Rs 121.72 crore, up 18.96% Y-o-Y
24.11.2025
Syncom Formula Standalone September 2025 Net Sales at Rs 121.44 crore, up 19.65% Y-o-Y
22.08.2025
Syncom Formula Standalone June 2025 Net Sales at Rs 116.55 crore, up 34.22% Y-o-Y
20.05.2025
Syncom Formula Consolidated March 2025 Net Sales at Rs 148.88 crore, up 99.64% Y-o-Y
26.11.2025
Syncom Formula Consolidated September 2025 Net Sales at Rs 121.72 crore, up 18.96% Y-o-Y
24.11.2025
Syncom Formula Standalone September 2025 Net Sales at Rs 121.44 crore, up 19.65% Y-o-Y
22.08.2025
Syncom Formula Standalone June 2025 Net Sales at Rs 116.55 crore, up 34.22% Y-o-Y
20.05.2025
Syncom Formula Consolidated March 2025 Net Sales at Rs 148.88 crore, up 99.64% Y-o-Y
19.03.2026
19.03.2026
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth